BAM
ESPR

Byrne Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Byrne Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,600
Closed -$14.5K – 572
2024
Q4 		$14.5K Buy
+6,600
New +$15.4K 0.01% 342

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Byrne Asset Management's ESPR Position: Q1 2025 in Review

Byrne Asset Management sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 6,600 shares — an estimated $14.5K sold.

Byrne Asset Management first reported a position in ESPR in Q4 2024 and held it in 1 quarter. The position peaked at $14.5K in Q4 2024. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • Byrne Asset Management reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Byrne Asset Management sold 6,600 Esperion Therapeutics shares in Q1 2025, an estimated $14.5K.
  • Byrne Asset Management first reported a position in Esperion Therapeutics in Q4 2024 and held it in 1 quarter.
  • Byrne Asset Management's Esperion Therapeutics position peaked at $14.5K in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Byrne Asset Management's 13F filing for Q1 2025, filed 16 Apr 2025.